natgillin/translations-raw huggingface dataset:
A method of making the composition of claim 11, comprising providing a suspension of mesoporous silica rods wherein said rods comprise a length of 5µm to 500 µm, and contacting said rods with said vaccine antigen, said immune cell recruitment compound, and said immune cell activation compound. 
Postupak za izradu pripravka prema zahtjevu 11, naznačen time što sadrži dobivanje suspenzije mezoporoznih silicijskih štapića pri čemu navedeni štapići sadrže duljinu od 5 µm do 500 µm i kontaktiranje navedenih štapića s navedenim antigenom cjepiva, navedenim spojem za regrutiranje imunoloških stanica i navedenim imunološkim staničnim aktivacijskim spojem.
The method of claim 12, wherein said rods are modified with glycolic acid or lactic acid prior to contacting said rods with said vaccine antigen, recruitment compound, or activation compound. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što su navedeni štapići modificirani s glikolnom ili mliječnom kiselinom prije kontakta navedenih štapića s navedenim antigenom cjepiva, spojem za regrutaciju ili aktivacijskim spojem.
The composition of claim 1 for injection and in vivo self-assembly of a 3D structure, wherein said structure comprises micro spaces that allow for cell infiltration or trafficking. 
Pripravak prema zahtjevu 1, naznačen time, da injekcija i in vivo samostalno sklapanje 3D strukture, pri čemu navedena struktura sadrži mikro prostore koji omogućavaju infiltraciju ili promet stanica.
The composition of claim 1, wherein said rods are stacked into a 3D structure, and wherein said structure comprises micro spaces that allow for cell infiltration or trafficking. 
Pripravak prema zahtjevu 1, naznačen time da su navedeni štapići složeni u 3D strukturu i gdje navedena struktura sadrži mikro prostore koji omogućuju infiltraciju ili promet stanica.
The composition of claim 1, wherein said immune cell recruitment compound comprises GM-CSF and said TLR agonist comprises CpG-ODN or PEI-CpG-ODN. 
Sastav prema zahtjevu 1, naznačen time, što navedeni spoj za regrutiranje imunoloških stanica sadrži GM-CSF i navedeni TLR agonist sadrži CpG-ODN ili PEI-CpG-ODN.
A method of monitoring a property of a coating (104, 1004 1104) of an at least partially solid dosage form (102, 1000, 1202) during a coating process forming the coating of the solid dosage form, the method comprising forming the coating on the solid dosage form, during the forming of the coating of the solid dosage form, simultaneously monitoring the property of the coating of the solid dosage form in process, wherein the property of the coating of the solid dosage form is monitored using low coherence interferometry. 
Postupak praćenja svojstva prevlake (104, 1004, 1104) barem djelomično čvrstog oblika doziranja (102, 1000, 1202) tijekom postupka nanošenja koji tvori prevlaku čvrstog oblika doziranja, naznačen time, da postupak uključuje oblikovanje prevlaka na čvrstom obliku doziranja, tijekom formiranja prevlake čvrstog oblika doziranja, istovremeno nadzire svojstvo prevlake čvrstog oblika doziranja u postupku, pri čemu se svojstva prevlake čvrstog oblika doziranja prate uređajima za praćenje koji koriste interferometriju niske koherencije, premještajući čvrsti oblik doziranja tijekom postupka oblaganja u vidno polje uređaja za praćenje.
The device according to claim 13, wherein the property of the coating is monitored in a time resolved manner. 
Uređaj u skladu s patentnim zahtjevom 13, naznačen time, da je uređaj prilagođen tako da se svojstvo prevlake prati vremenski razlučenim načinom.
The antibody, or binding fragment thereof, according to any one of claims 1 to 7, 11, or 12, wherein said antibody further comprises an Fc variant, wherein the Fc region comprises at least one non naturally occurring amino acid selected from the group consisting of 234F, 235F, and 331 S, as numbered by the EU index as set forth in Kabat. 
Protutijelo ili njegov fragment za vezanje prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen/o time, da navedeno protutijelo nadalje obuhvaća Fc varijantu, gdje Fc područje sadrži najmanje jednu aminokiselinu koja se ne pojavljuje prirodno, odabranu iz skupine koju čine 234F, 235F i 331S, prema numeriranju u skladu s EU indeksom prikazanim u Kabat sustavu.
one or more parenteral solvents, 
jedno ili više parenteralnih otapala;
An implantable prosthetic valve, comprising: 
Postupak sklapanja protetskog zaliska koji se može implantirati koji sadrži:
The composition according to claim 8, wherein the chelating agent is citric acid. 
Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je kelirajuće sredstvo limunska kiselina.
A process for preparing the composition according to any one of claims 1 to 10 comprising dissolving arginine, pemetrexed diacid, the monothiolic antioxidant, optionally the chelating agent and propylene glycol in the solvent, making up the volume using water, filtrating and filling the glass vials. 
Postupak priprave pripravka u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što se sastoji u otapanju arginina, dikiseline pemetrekseda, monotiolnog antioksidansa, izborno kelirajućeg sredstva i propilen-glikola u otapalu, dopunjavanju volumena vodom, filtriranju i punjenju staklenih bočica.
The process according to claim 11 comprising the step of terminal sterilization. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se sastoji u koraku terminalne sterilizacije.
The composition according to any one of claims 1 to 10 for use in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u liječenju zloćudnog mezotelioma poprsnice i raka velikih stanica pluća.
Connecting system according to one of the preceding claims, characterized in that by rotating the connecting arrangements (3A, 3B, 3A', 3B') relative to one another, particularly about a common axis (9), the deformation is produced by the rotation and/or the opening region (4A, 4A') of the first connecting arrangement (3A, 3A') is opened. 
Spojni sustav prema jednom od prethodnih patentnih zahtjeva, naznačen time, da se putem okretanja spojnih rasporeda (3A, 3B, 3A', 3B') jednog u odnosu na drugi, prvenstveno oko zajedničke osi (9), proizvodi deformacija pomoću okretanja i /ili se otvara prostor za otvaranje (4A, 4A') od prvog spojnog rasporeda (3A, 3A').
Connecting system according to one of the preceding claims, characterized in that the second connecting arrangement (3B, 3B') comprises an, in particular, film-like, brittle and/or unstable opening region (4B, 4B'), wherein preferably the first connecting arrangement (3A, 3A') is configured to open the second connecting arrangement (3B, 3B'). 
Spojni sustav prema jednom od prethodnih patentnih zahtjeva, naznačen time, da drugi spojni raspored (3B, 3B') obuhvaća jedan, prvenstveno nalik na foliju, lomljiv i/ili nestabilan prostor za otvaranje (4B, 4B'), pri čemu je poželjno prvi spojni raspored (3A, 3A') oblikovan tako, da otvori drugi spojni raspored (3B, 3B').
Connecting system according to claim 7, characterized in that the first connecting arrangement (3A, 3A') is configured to open the second connecting arrangement (3B, 3B') by breaking through the opening region (4B, 4B') of the second connecting arrangement (3B, 3B'). 
Spojni sustav prema patentnom zahtjevu 7, naznačen time, da je prvi spojni raspored (3A, 3A') oblikovan tako, da otvori drugi spojni raspored (3B, 3B') pomoću prodiranja u prostor za otvaranje (4B, 4B') od drugog spojnog rasporeda (3B, 3B').
Connecting system according to one of the preceding claims, characterized in that the fluidic connection (2) can be produced by, preferably mutual, opening of the two connecting arrangements (3A, 3B, 3A', 3B') or their opening regions (4A, 4B, 4A', 4B'). 
Spojni sustav prema jednom od prethodnih patentnih zahtjeva, naznačen time, da se fluidna veza (2) može proizvesti pomoću, poželjno zajedničkog, otvaranja dva spojna rasporeda (3A, 3B, 3A', 3B') ili njihovih prostora za otvaranje (4A, 4B, 4A', 4B').
An integral metal end cap according to claim 1 wherein the openings are longitudinal, have the same length and are parallel to the longitudinal axis of the integral metal end cap. 
Integrirani metalni poklopac u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time, da su otvori postavljeni uzdužno, iste su duljine i paralelni su s uzdužnom osi keramičkog valjka.
at least at one end of the ceramic spool, a metal end cap according to claim 1 . 
barem na jednom kraju keramičkog valjka, metalni poklopac (3) u skladu s bilo kojim od patentnih zahtjeva 1 do 7.
The pharmaceutically acceptable liquid composition of claim 7, wherein the agent is L-cysteine, N-acetylcysteine (NAC), gluthatione (GSH), Na2-EDTA, Na2-EDTA-Ca, sodium bisulfite, or a combination thereof. 
Farmaceutski prihvatljivi tekući pripravak u skladu s patentnim zahtjevom 7, naznačen time što je sredstvo l-cistein, N-acetilcistein (NAC), glutation (GSH), Na2-EDTA, Na2-EDTA-Ca, natrijev bisulfit, ili njihova kombinacija.
0.05-5.0 wt% of a natural moisturizing agent (e.g. natural yogurt or yogurt derivatives or milk fermentation products or honey or honey products or mixtures thereof) 
0.05-5.0 mas.% prirodnog jogurta ili derivata jogurta ili proizvoda fermentacije mlijeka ili od meda ili proizvoda od meda ili njihovih mješavina,
A preparation according to claim 1, wherein the total amount of (b) hyaluronic acid, a salt thereof or mixtures thereof is preferably 0.1-2.0 wt%, based on the total weight of the composition. 
Preparat prema zahtjevu 1, naznačen time što je ukupna količina (b) hijaluronske kiseline, njene soli ili njihove mješavine od 0.1-2.0 mas.%, u odnosu na ukupnu masu pripravka.
A preparation according to any of the above-mentioned claims, wherein the composition further contains anti-irritant agents, antioxidants, buffering agents, chelating agents, emollients, penetration enhancing agents, solubilizing agents, thickening agents, wetting agents or mixtures thereof. 
Preparat prema bilo kojem od gore spomenutih zahtjeva, naznačen time što pripravak nadalje sadrži sredstva protiv nadraživanja, antioksidante, puferirajuća sredstva, kelatna sredstva, emolijense, sredstva za pojačavanje penetracije, sredstva za otapanje, sredstva za zgušnjavanje, sredstva za vlaženje ili njihove mješavine.
is selected from the group consisting of: H, 3H, halo and C1-3alkyl; 
je izabran iz grupe koja obuhvaća: H, 3H, halo i C1-3alkil;
ring A is selected from the group consisting of: 
prsten A je izabran iz grupe koja obuhvaća:
R3b is selected from the group consisting of: C1-5alkyl optionally substituted with OH or OCH3; C1-5haloalkyl; benzyl; CH2cyclopropyl; cyclopropyl optionally substituted with C1-5alkyl; and cyclobutyl; and 
b je izabran iz grupe koja obuhvaća: C1-5alkil opcionalno supstituiran s OH ili OCH3; C1-5haloalkil; benzil; CH2ciklopropil; ciklopropil opcionalno supstituiran s C1-5alkil; i ciklobutil; i
is phenyl optionally substituted with two halo; and 
je fenil opcionalno supstituiran s dva halo; i
The method of claim 21, wherein the inflammatory respiratory disease is selected from the group consisting of asthma, sinusitis, hay fever, bronchitis, chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute and chronic otitis, and lung fibrosis. 
Peptid ili farmaceutski pripravak za uporabu prema patentnom zahtjevu 10, naznačeni time što je upalna respiratorna bolest odabrana iz grupe koja se sastoji od: astme, sinusitisa, peludne groznice, bronhitisa, kronične opstruktivne bolesti pluća (COPD), alergijskog rinitisa, akutnog i kroničnog otitisa, i plućne fibroze.
The composition according to claim 1, wherein the composition is a gel, spray, ointment, cream or patch for transdermal use and it comprises 0.1-1000 mg/ml of MK-467 and 0.01-500 mg/ml of the a2-adrenoceptor agonist. 
Pripravak za medicinsku upotrebu za sedaciju prema bilo kojem patentnom zahtjevu 1-6, naznačen time da je pripravak gel, sprej, mast, krema ili flaster za transdermalnu upotrebu i da sadrži 0.1-1000 mg/ml MK-467 i 0.01-500 mg/ml agonista a2- adrenoceptora.
or a pharmaceutically acceptable salt thereof, wherein: 
[image] ili njegova farmaceutski prihvatljiva sol, pri čemu:
The method according to claim 5, wherein the cocoa pulp and mucilage obtained in the depulping step is processed separately from the unfermented cocoa beans and subsequently added to the suspension before or during steps (a), (b), (c) or (d). 
Komplet za proizvodnju čokolade ili čokoladi sličnih proizvoda u skladu s patentnim zahtjevom 5, naznačen time što se u navedenom postupku kakaovu pulpu i biljnu sluz dobivene u koraku depulpiranja obradi odvojeno od nefermentiranih zrna kakaa, te naknadno doda u suspenziju prije ili tijekom koraka (a), (b), (c) ili (d).
The method according to claim 6, wherein the processing of the cocoa pulp and mucilage comprises neutralizing and/or removing acidic components. 
Komplet za proizvodnju čokolade ili čokoladi sličnih proizvoda u skladu s patentnim zahtjevom 6, naznačen time što se u navedenom postupku obrada kakaove pulpe i biljne sluzi sastoji u neutraliziranju i/ili uklanjanju kiselih komponenata.
conching said mixture; 
končiranja navedene smjese;
Process for the production of a fragmentation projectile according to claim 1, wherein the projectile is produced by “Powder Bed Laser Beam Technology” (LBM) process, whereby crevices are created with the radiation source temporarily switched off for such a length of time that, of the fed or existing metal or ceramic or polymer powder, 1 to 6 grains are not melted or sintered. 
Postupak za proizvodnju fragmentacijskog projektila (1-1") prema patentnom zahtjevu 1, naznačen time što je projektil (1-1") proizveden tehnološkim postupkom "laserske zrake s praškastim slojem" (LBM), pri čemu pukotine (8) stvorene s izvorom zračenja su privremeno isključene tako dugo dok se, iz napunjenog ili postojećeg metalnog, keramičkog ili polimernog praha, ne rastopi ili sinterira 1 do 6 zrnaca.
Process for the production of a fragmentation projectile according to claim 1, wherein the projectile is produced by “Powder Bed Laser Beam Technology” (LBM) process, with a grain size of 53 μm to 99%, consisting of Cu 77.0%, Ni 14.7%, Sn 6.8% and P 1.5% (percent by weight). 
Postupak za proizvodnju fragmentacijskog projektila (1-1") prema patentnom zahtjevu 1 ili 2, naznačen time što je projektil (1-1") proizveden tehnološkim postupkom "laserske zrake s praškastim slojem" (LBM) s veličinom zrna od 53 µm do 99%, koja se sastoje od Cu 77,0%, Ni 14,7%, Sn 6,8% i P 1,5% (težinski postotci).
Fragmentation projectile produced by additive manufacturing (AM) according to claim 6, wherein at least a part of the segments comprises a composite material. Fragmentation projectile produced by additive manufacturing (AM) according to claim 16, wherein the composite material contains ceramics and/or polymers. 
Fragmentacijski projektil (1-1") proizveden aditivnom proizvodnjom (AM) prema patentnom zahtjevu 6, naznačen time što se najmanje jedan dio segmenata sastoji od kompozitnog materijala, pri čemu kompozitni materijal naročito sadrži keramike i/ili polimere.
at least one thickening agent: 4 to 16 g/I of suspension; 
najmanje jedno sredstvo za zgušnjavanje i/ili suspendiranje: 4 do 16 g/l suspenzije;
buffering agent so as to adjust to the desired pH. 
sredstvo za puferiranje kako bi se podesilo željeni pH.
sweetening agent: 550 to 650 g/I of suspension; and/or 
zaslađivač: 550 do 650 g/l suspenzije; i/ili
An aqueous suspension of enkephalinase inhibitor according to anyone of the preceding claims for use for the treatment and/or prevention of diarrhoea, acute gastroenteritis, and/or acute diarrhoea associated with emesis. 
Vodena suspenzija racedotrila prema bilo kojem od prethodnih zahtjeva naznačen time što je upotrebu u liječenju i/ili sprječavanju proljeva, akutnog gastroenteritisa, i/ili akutnog proljeva povezanog s povraćanjem.
The pharmaceutical composition of any one of claims 1 to 6, wherein said anti-human IL13 antibody or antigen binding fragment thereof binds to the same epitope as the antibody produced by hybridoma 228B/C-1 (PTA-5657). 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time što se navedeno anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen veže na isti epitop kao i antitijelo proizvedeno hibridomom 228B/C-1 (PTA-5657).
a support structure (2); 
potpornu strukturu (2);
means (4) for driving said rotation shafts (3) in order to rotate them around their longitudinal extension axis (Y); 
sredstvo (4) za pokretanje navedenih rotacijskih osovina (3) kako bi one rotirale oko longitudinalne produžne osovine (Y);
Disk screen for separating solid residues according to claim 1, characterized in that said depressions (12) are perimetrically delimited by a sunken edge (120) facing, to size, the circumferential profile (113) of said annular shoulders (13). 
Disk sito za razdvajanje čvrstih ostataka prema patentnom zahtjevu 1, naznačeno time što su navedena udubljenja (12) po obodu ograničena spuštenim rubom (120) iste veličine kao i kružni obodni profil (113) navedenih prstenastih ramena (13) prema kojima je okrenuta.
Disk screen for separating solid residues according to claim 1, characterized in that the lateral areas of said annular shoulders (13) are embedded within said central depressions (12). 
Disk sito za razdvajanje čvrstih ostataka prema patentnom zahtjevu 1, naznačeno time što su bočne oblasti navedenih prstenastih ramena (13) smještene unutar navedenih centralnih udubljenja (12).
Pharmaceutical composition according to Claim 1, which is a tablet packaged into a cold-formed blister (so-called cold blister /CFF/) of OPA/AL/PVC composite foil covered with an aluminium lidding foil, or into a blister of thermoformable, damp-proof composite foil and covered with an aluminium lidding foil, or into a glass or polypropylene vessel equipped with an airtight container cap of polyethylene or polypropylene, comprising 1%-6% of amlodipine besylate, 1%-6% of bisoprolol fumarate, 80%-90% of microcrystalline cellulose, 4%-6% of sodium starch glycolate, 1%-2% of magnesium stearate, 0.5%-1% of colloid silica based on the weight of the tablet. 
Ambalažirani oblik doziranja u skladu s patentnim zahtjevom 4, naznačen time što se tabletu ambalažira u hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije, pokrivene aluminijskom pokrovnom folijom, ili u blister od kompozitne folije koju se može toplinski oblikovati otporne na vlagu i pokrivene aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu poklopcem od polietilena ili polipropilena za spremnike nepropustnim za zrak, gdje homogeni pripravak sadrži 1%-6% amlodipin-besilata, 1%-6% bisoprolol-fumarata, 80%-90% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tablete.
Pharmaceutical composition according to Claim 1, which is a capsule packaged into a cold-formed blister (so-called cold blister /CFF/) of OPA/AL/PVC composite foil covered with an aluminium lidding foil, or into a blister of thermoformable damp-proof composite foil and covered with an aluminium lidding foil, or into a glass or polypropylene vessel equipped with an airtight container cap of polyethylene or polypropylene, comprising 10%-15% of amlodipine besylate, 10%-15% of bisoprolol fumarate, further 55%-65% of microcrystalline cellulose, 4%-6% of sodium starch glycolate, 1%-2% of magnesium stearate, 0.5%-1% of colloid silica based on the weight of the filling substance of the capsule. 
Ambalažirani oblik doziranja u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što se kapsulu ambalažira u hladno oblikovani blister (tzv. hladni blister /CFF/) od OPA/AL/PVC kompozitne folije, pokrivene aluminijskom pokrovnom folijom, ili u blister od kompozitne folije koju se može toplinski oblikovati otporne na vlagu i pokrivene aluminijskom pokrovnom folijom, ili u staklenu ili polipropilensku posudu opremljenu poklopcem od polietilena ili polipropilena za spremnike nepropusnim za zrak, gdje homogeni pripravak sadrži 10%-15% amlodipin-besilata, 10%-15% bisoprolol-fumarata, dodatno 55%-65% mikrokristalne celuloze, 4%-6% karboksimetilškrob-natrija, 1%-2% magnezijevog stearata, 0,5%-1% koloidnog silicijevog dioksida na osnovi težine tvari za punjenje kapsule.
b.) filled into hard gelatine capsules in a known manner, then the obtained tablets or capsules are packaged into damp-proof protecting packages in a known manner. 
) homogenizat puni u tvrde želatinske kapsule na poznati način, zatim se dobivene tablete ili kapsule ambalažira u zaštitna pakiranja otporna na vlagu na poznati način.
Composition according to one of claims 1 to 13, for use in the treatment and/or prevention of polycystic ovary syndrome, insulin resistance, hyperinsulinemia, hyperglycemia, hyperandrogenism, metabolic syndrome, dyslipidemia, type 2 diabetes mellitus and cardiovascular/cerebrovascular diseases, in Medically Assisted Procreation (MAP) therapies in order to improve oocyte quality, and to optimize ovarian hyperstimulation protocols; in particular to prevent ovarian hyperstimulation syndrome, irritability, hypertension, osteoporosis, dyslipidemia, weight gain, hot flushes and aging of the skin. 
Meka kapsula prema bilo kojem od prethodnih zahtjeva, naznačena time, da se upotrebljava za liječenje i / ili sprječavanje sindroma policističnih jajnika, inzulinske rezistencije, hiperinzulinemije, hiperglikemije, hipendrondrogenizma, metaboličkog sindroma, dylidididemije, šećerne bolesti tipa 2 i kardiovaskularnog / cerebrovaskularne bolesti, u terapiji medicinski potpomognute oplodnje (MAP) radi poboljšanja kvalitete oocita i optimizacije protokola hiperstimulacije jajnika; posebno za sprječavanje sindroma hiperstimulacije jajnika, razdražljivosti, hipertenzije, osteoporoze, dislipidemije, debljanja, vrućice i starenja kože.
The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a solid pharmaceutical composition. 
Farmaceutski sastav prema zahtjevu 1, gdje je farmaceutski sastav čvrsti farmaceutski sastav.
The pharmaceutical composition of claim 1 or claim 2, further comprising a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
Farmaceutski sastav prema zahtjevu 1 ili 2, koji dalje sadrži farmaceutski prihvatljiv nosač, adjuvant ili sredstvo.
The pharmaceutical composition of any preceding claim for use in treating cystic fibrosis in a mammal, wherein said use comprises administering to said mammal an effective amount of the pharmaceutical composition. 
Farmaceutski sastav prema bilo kojem prethodnom zahtjevu za upotrebu u liječenju cistične fibroze kod sisavca, gdje spomenuta upotreba obuhvaća davanje spomenutom sisavcu efikasne količine farmaceutskog sastava.
The pharmaceutical composition of any of claims 1-3, wherein the substantially amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide is in the form of a solid dispersion. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1-3, gdje je amorfni N-[2,4-bis(1,11-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksokinolin-3-karboksamid u obliku čvrste disperzije.
The pharmaceutical composition of any of claims 1, 2, 3, 5, or 7, further comprising a polymer. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1, 2, 3, 5 ili 7, što dalje sadrži polimer.
preparing a solution in a crystallization vessel of canagliflozin in a solvent system comprising water in an amount from 0.37 wt % to 1.50 wt % under concentration and temperature conditions which allow the complete dissolution of canagliflozin; 
pripremanje otopine u posudi za kristalizaciju kanagliflozina u sustavu otapala koji sadrži vodu u količini od 0,37 mas.% do 1,50 mas.% u uvjetima koncentracije i temperature koji omogućuju potpuno otapanje kanagliflozina;
seeding the solution of step b) with crystalline canagliflozin hemihydrate; 
sijanje otopine iz koraka b) s kristalnim kanagliflozin hemihidratom;